Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Cobo Marc, holds the title of Principal Accounting Officer at BridgeBio Oncology Therapeutics, Inc..
On 2026-07-01, the insider transacted 125 shares.The shares were transacted at a weighted average price of $7.80 per share, resulting in a total market-relevant value of $975.
Cobo Marc (Principal Accounting Officer) had withheld for taxes $975 of $BBOT
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.